News

Patients with non-muscle invasive bladder cancer seek improved communication with providers about treatment options, highlighting a need for collaborative care discussions.

Explore the evolving role of medical oncologists in treating non–muscle invasive bladder cancer with innovative immunotherapy options and trial insights.

Eflornithine combined with lomustine shows promising survival benefits for patients with recurrent IDH-mutant grade 3 astrocytoma in recent trials.

The FDA approves enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, significantly improving survival rates post-surgery.

Zipalertinib shows promise as a treatment for advanced NSCLC with EGFR mutations, demonstrating significant response rates in recent trials.

The JULIET trial reveals long-term efficacy and safety of CAR-T therapy tisagenlecleucel in relapsed/refractory large B-cell lymphoma patients.

A clinical study reveals that combining third-generation tyrosine kinase inhibitors with azacitidine effectively treats chronic myeloid leukemia, showing promising patient outcomes.

High LAG3 expression in metastatic renal cell carcinoma enhances initial immunotherapy response but does not improve long-term survival outcomes.

During a live event, Hannah Choe, MD, discussed options for steroid-resistant cGVHD based on organ involvement, efficacy, and safety profiles.

The FDA approves new denosumab biosimilars, expanding treatment options for osteoporosis and cancer-related bone issues, enhancing patient access to care.

The FDA reviews zidesamtinib for advanced ROS1+ NSCLC, promising new treatment options for patients resistant to current therapies.

A novel combination therapy shows promising results in extending progression-free survival for patients with advanced pancreatic cancer, highlighting potential biomarkers for immunotherapy.

New research reveals that high CD8-positive T-cell infiltration worsens outcomes for ovarian cancer patients treated with bevacizumab, challenging existing prognostic models.

Neladalkib shows promising efficacy in advanced ALK+ NSCLC, offering durable responses and manageable safety, potentially transforming treatment options.

The FDA has granted a full approval to tarlatamab-dlle for extensive-stage small cell lung cancer.

The FDA has approved sevabertinib for HER2-mutant nonsquamous non–small cell lung cancer.

The FDA has approved daratumumab and hyaluronidase plus chemotherapy for treating patients with newly diagnosed light chain amyloidosis.

Olutasidenib shows promising long-term efficacy and safety in treating relapsed or refractory mutant IDH1 acute myeloid leukemia, enhancing patient outcomes.

A novel sandwich therapy combining CD22/CD19 CAR T-cell therapy and autologous stem cell transplantation shows remarkable efficacy in treating Ph-negative B-ALL.

The FDA approves selumetinib for adults with neurofibromatosis type 1, offering new hope for treating inoperable plexiform neurofibromas.

Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, transforming treatment options for patients.

Giredestrant shows promise as a groundbreaking treatment for early-stage breast cancer, significantly improving disease-free survival rates.

Highlands Oncology's innovative remote monitoring model enhances cancer care, reducing ED visits and improving treatment adherence through effective symptom management.

During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens for non–clear cell renal cell carcinoma.

Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.

OBI-902 receives FDA orphan drug designation for cholangiocarcinoma, promising new hope in treating this rare and aggressive cancer.

Small cell lung cancer treatment evolves with groundbreaking therapies, improving survival rates and offering new hope for patients in 2024 and beyond.

The FDA approves epcoritamab with rituximab and lenalidomide for relapsed follicular lymphoma, offering a new second-line treatment option.